Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.

Try Elite for Free

The Finviz API: Higher Limits, Clearer Data, and More Ways to Connect

Get Started Now

PMV Pharmaceuticals, Inc.

Contributing Author

Recent Articles by PMV Pharmaceuticals, Inc.

Oct-05	PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors PMVP GlobeNewswire
Sep-08	PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer PMVP GlobeNewswire
Aug-31	PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities PMVP +6.61% GlobeNewswire
Aug-31	PMV Pharma Announces Proposed Public Offering of Securities PMVP PMVP +6.61% GlobeNewswire
Aug-31	PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial PMVP PMVP +6.61% GlobeNewswire
Aug-14	PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights PMVP GlobeNewswire
May-12	PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights PMVP GlobeNewswire
Apr-22	PMV Pharmaceuticals Announces Board Chair Transition PMVP GlobeNewswire
Mar-06	PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights PMVP +7.19% GlobeNewswire
Feb-26	New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors PMVP +22.32% GlobeNewswire
Nov-12	PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights PMVP +6.77% GlobeNewswire
Oct-24	PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation PMVP GlobeNewswire
Oct-13	PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics PMVP PMVP +7.58% GlobeNewswire
Sep-10	PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation PMVP -20.63% GlobeNewswire
Aug-07	PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights PMVP GlobeNewswire
May-23	PMV Pharmaceuticals to Participate at Upcoming Investor Conferences PMVP GlobeNewswire
May-09	PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights PMVP GlobeNewswire

Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)